IKOULA
9.12.2021 10:02:06 CET | Business Wire | Press release
The French specialist in web hosting, dedicated servers and cloud computing IKOULA announced a joint case study with the leading open-source cloud management software CloudStack. For the management of their cloud environment, IKOULA decided to choose the open-source way by combining the power of CloudStack with the simplicity of the open-source hypervisor XCP-ng. Тhe turnkey combination was carefully selected following the long-term company strategy to guarantee a constant product evolution, reliability and simplicity for their customers. As a result, IKOULA is now among the most innovative cloud and managed services providers in Europe, with an extensive portfolio of cloud solutions. Moreover, a large number of customers use their CloudStack-orchestrated infrastructure to deploy memory-oriented and storage-oriented VMs or Kubernetes clusters.
The cloud and hosting market is one of the most competitive in the tech industry. Companies need to constantly innovate, be creative, offer exceptional service quality and support while keeping a competitive price. Choosing an open-source technology stack is a strategic decision taken by IKOULA. They eliminate all vendor lock-ins and ensure the company has full control over their infrastructure by being open-source. Other significant benefits are the easy management of extensive infrastructure, guaranteed reliability, and seamless scalability.
“It is essential for us as a hosting company to know exactly what is running on our servers. This is a decisive advantage in terms of security.
We decided to go with open-source solutions, as they deliver the reliability and flexibility we need. When it comes to debugging issues, we can quickly look in the code and fix it or ask the community for help on the error. CloudStack and XCP-ng have an active and growing community and constantly evolving products, which is a huge benefit”, said Joaquim Dos Santos, R&D Director at Ikoula.
CloudStack and XCP-ng also give a financial advantage to IKOULA, which is extremely important in their market segment. According to their team, operating XCP-ng and CloudStack results in greatly reduced costs than other solutions. They have also greatly reduced their reliance on 3rd parties to help maintain their environment.
At this stage, IKOULA manages a large CloudStack environment with 100+ hosts in 8 different zones and 6600+ customers using it. They can make live updates and upgrades of the system without any service interruptions for the end-users. Among the most valuable CloudStack features for them are the multi-tenancy of the solution, its scalability and the power to easily manage hundreds of hosts and thousands of VMs.
About IKOULA
Pioneer of the French Cloud since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and in the Netherlands. Because people are part of its DNA, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in their activities. IKOULA's teams are also multilingual, in order to respond to the internationalization issues of all of its customers, located in more than 60 countries on 4 continents. Since September 2021, IKOULA has joined of the SEWAN Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom